PTC Therapeutics (FRA:BH3) E10: €-4.01 (As of Mar. 2026)


FRA:BH3 PTC Therapeutics Inc FRA:BH3
51 GF Score
Price €72.26
GF Value €30.17
! 9 Warning Signs
View Full Analysis

What is PTC Therapeutics E10?

PTC Therapeutics FRA:BH3 +0.36% 51 E10 is €-4.01 as of Mar. 2026. GuruFocus rates FRA:BH3 with a GF Score™ of 51/100 and a GF Value™ of €30.17. The stock has 9 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

PTC Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.026. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-4.01 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was 6.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of PTC Therapeutics was 6.40% per year. The lowest was -7.70% per year. And the median was -0.65% per year.

As of today (2026-06-29), PTC Therapeutics's current stock price is €72.26. PTC Therapeutics's E10 for the quarter that ended in Mar. 2026 was €-4.01. PTC Therapeutics's Shiller PE Ratio of today is .


PTC Therapeutics  (FRA:BH3) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


PTC Therapeutics E10 Related Terms


PTC Therapeutics E10 Historical Data

* Premium members only.

The historical data trend for PTC Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PTC Therapeutics E10 Chart

PTC Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.43 -5.39 -5.53 -5.91 -4.17

PTC Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.97 -4.42 -4.12 -4.17 -4.01

FRA:BH3 vs SRRK, COGT, RYTM: E10 Comparison

For the Biotechnology subindustry, PTC Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PTC Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where PTC Therapeutics's Shiller PE Ratio falls into.


FRA:BH3
51GF Score
PTC Therapeutics Inc FRA:BH3
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PTC Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, PTC Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.026/330.2130*330.2130
=-0.026

Current CPI (Mar. 2026) = 330.2130.

PTC Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201606 -1.015 241.018 -1.391
201609 -0.918 241.428 -1.256
201612 -0.739 241.432 -1.011
201703 -0.795 243.801 -1.077
201706 -0.392 244.955 -0.528
201709 -0.688 246.819 -0.920
201712 0.025 246.524 0.033
201803 -0.373 249.554 -0.494
201806 -0.180 251.989 -0.236
201809 -0.908 252.439 -1.188
201812 -0.844 251.233 -1.109
201903 -1.142 254.202 -1.483
201906 -0.664 256.143 -0.856
201909 -0.962 256.759 -1.237
201912 -1.233 256.974 -1.584
202003 -1.638 258.115 -2.096
202006 -2.469 257.797 -3.163
202009 -0.874 260.280 -1.109
202012 -0.863 260.474 -1.094
202103 -1.537 264.877 -1.916
202106 -1.394 271.696 -1.694
202109 -1.607 274.310 -1.934
202112 -1.797 278.802 -2.128
202203 -1.616 287.504 -1.856
202206 -2.015 296.311 -2.246
202209 -1.545 296.808 -1.719
202212 -2.218 296.797 -2.468
202303 -1.756 301.836 -1.921
202306 -2.455 305.109 -2.657
202309 -1.649 307.789 -1.769
202312 -1.889 306.746 -2.034
202403 -1.104 312.332 -1.167
202406 -1.198 314.175 -1.259
202409 -1.252 315.301 -1.311
202412 -0.812 315.605 -0.850
202503 9.287 319.799 9.589
202506 -0.720 322.561 -0.737
202509 0.170 324.800 0.173
202512 -1.426 324.054 -1.453
202603 -0.026 330.213 -0.026

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-4.01 mean?
PTC Therapeutics (FRA:BH3) has a E10 of €-4.01 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on PTC Therapeutics and its competitors.
Is PTC Therapeutics' E10 too high?
PTC Therapeutics' current E10 is €-4.01. Overall, PTC Therapeutics has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does PTC Therapeutics' E10 compare to SRRK and COGT?
PTC Therapeutics' E10 of €-4.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on PTC Therapeutics and its competitors. PTC Therapeutics's current E10 is €-4.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PTC Therapeutics stock overvalued right now?
PTC Therapeutics (FRA:BH3) has a current E10 of €-4.01. The stock's GF Value™ is €30.17, compared to a current price of €72.26 — trading 139.5% above its estimated fair value. The current E10 is €-4.01. PTC Therapeutics' overall GF Score™ is 51/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For PTC Therapeutics (FRA:BH3), the current E10 is €-4.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PTC Therapeutics (FRA:BH3) Overvalued in 2026?

Based on GuruFocus' analysis, PTC Therapeutics stock appears to be overvalued. The current stock price of €72.26 is trading 139.5% above its estimated GF Value™ of €30.17.

Key valuation signals for FRA:BH3:

  • E10: €-4.01
  • GF Value™: €30.17 vs. price of €72.26 (139.5% above fair value)
  • GF Score™: 51/100 with 9 warning signs

No single metric tells the full story. See the FRA:BH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PTC Therapeutics Business Description

Other Exchanges PTCT:USABH3:Germany
Address 500 Warren Corporate Center Drive, Warren, NJ, USA, 07059
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
51GF Score

Get the complete analysis for FRA:BH3

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€72.26
Price
€30.17
GF Value